Omidenepag isopropyl - Generic Drug Details

What are the generic drug sources for omidenepag isopropyl and what is the scope of freedom to operate?

Omidenepag isopropyl is the generic ingredient in one branded drug marketed by Visiox Pharma and is included in one NDA. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Omidenepag isopropyl has one hundred and twenty-nine patent family members in thirty-two countries.

One supplier is listed for this compound.

Summary for omidenepag isopropyl

International Patents:	129
US Patents:	11
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	22
Clinical Trials:	1
Patent Applications:	44
What excipients (inactive ingredients) are in omidenepag isopropyl?	omidenepag isopropyl excipients list
DailyMed Link:	omidenepag isopropyl at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for omidenepag isopropyl

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

Dosage:

SOLUTION;OPHTHALMIC

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for omidenepag isopropyl

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Santen Pharmaceutical Asia Pte. Ltd.	Phase 4

See all omidenepag isopropyl clinical trials

Pharmacology for omidenepag isopropyl

Drug Class	Prostaglandin E2 Receptor Agonist
Mechanism of Action	Prostaglandin E2 Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for omidenepag isopropyl

S01EX	Other antiglaucoma preparations
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for omidenepag isopropyl

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Visiox Pharma	OMLONTI	omidenepag isopropyl	SOLUTION;OPHTHALMIC	215092-001	Sep 22, 2022		DISCN	Yes	No
Visiox Pharma	OMLONTI	omidenepag isopropyl	SOLUTION;OPHTHALMIC	215092-001	Sep 22, 2022		DISCN	Yes	No				Y
Visiox Pharma	OMLONTI	omidenepag isopropyl	SOLUTION;OPHTHALMIC	215092-001	Sep 22, 2022		DISCN	Yes	No			Y	Y
Visiox Pharma	OMLONTI	omidenepag isopropyl	SOLUTION;OPHTHALMIC	215092-001	Sep 22, 2022		DISCN	Yes	No			Y
Visiox Pharma	OMLONTI	omidenepag isopropyl	SOLUTION;OPHTHALMIC	215092-001	Sep 22, 2022		DISCN	Yes	No			Y
Visiox Pharma	OMLONTI	omidenepag isopropyl	SOLUTION;OPHTHALMIC	215092-001	Sep 22, 2022		DISCN	Yes	No			Y
Visiox Pharma	OMLONTI	omidenepag isopropyl	SOLUTION;OPHTHALMIC	215092-001	Sep 22, 2022		DISCN	Yes	No			Y

International Patents for omidenepag isopropyl

Country	Patent Number	Title	Estimated Expiration
China	105828818	含有吡啶基氨基乙酸化合物的药物组合物 (Pharmaceutical Composition Containing Pyridylamino Acetic Acid Compound)
Canada	2951784	COMPOSE SULFONAMIDE ET METHODE DE PRODUCTION DE CELUI-CI (N-SUBSTITUTED SULFONAMIDE COMPOUND AND METHOD FOR PRODUCING SAME)
European Patent Office	3733179	PRÉPARATION PHARMACEUTIQUE CONTENANT UN COMPOSÉ D'ACIDE PYRIDYLAMINOACÉTIQUE (PHARMACEUTICAL PREPARATION CONTAINING PYRIDYL AMINOACETIC ACID COMPOUND)
Canada	2935055	COMPOSITION PHARMACEUTIQUE CONTENANT UN COMPOSE ACIDE PYRIDYLAMINO-ACETIQUE (PHARMACEUTICAL COMPOSITION CONTAINING PYRIDYLAMINOACETIC ACID COMPOUND)
Georgia, Republic of	P20196982	PHARMACEUTICAL COMPOSITION CONTAINING PYRIDYLAMINO ACETIC ACID COMPOUND
South Korea	101681347
Croatia	P20160104